Dan Stanton

Andrew Mears, CEO of Lead Candidate, highlighted a dichotomy in the industry, where some sectors are downsizing while others are experiencing rapid growth during a video interview at Biotech Week Boston (BWB).

2025 will see increased biotech IPOs, spurred on by a “flight to quality” and declining interest rates, says William Blair analyst Kevin Eisele.

While much talk at CPHI Milan centered on the potential impact of BIOSECURE, other US policies – particularly the Inflation Reduction Act (IRA) – are proving a boon for Indian CDMOs.

CSL Behring will deprioritize ex vivo lentiviral-based gene therapies and shutter a facility in California as it converges its advanced therapy R&D operations to Waltham, Massachusetts.

The proposed acquisition of Evotec would essentially transform Halozyme from a therapeutics-based drug delivery platform into a full bioprocess services company.

Shore up supply chains? Bring manufacturing in-house? Look to Europe and India? With BIOSECURE looking increasingly likely, industry experts took to LinkedIn to discuss potential solutions if working with China-based suppliers is prohibited.

Pfizer, Merck & Co., and Moderna remain upbeat over future dealings with the US government despite President-elect Trump telling vaccine-sceptic and alternative-medicine proponents RFK Jr. and Dr Oz to “go wild on health.”

Multiple production lines, low bioburden control, and a solvent regeneration policy formed part of Novartis’s considerations when developing an inhouse oligonucleotide strategy.

Roche inked a $1.5 billion deal for off-the-shelf CAR-T partner Poseida Therapeutics in a week that saw its peer Novartis buy gene therapy developer Kate Therapeutics.

Under its “One Lonza” strategy, the CDMO will exit the capsules space to focus on three business units: Integrated Biologics, Advanced Synthesis, and Specialized Modalities.